Global trends in chronic kidney disease-related mortality : a systematic review protocol
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: In recent decades, all-cause mortality has increased among individuals with chronic kidney disease (CKD), influenced by factors such as aetiology, standards of care and access to kidney replacement therapies (dialysis and transplantation). The recent COVID-19 pandemic also affected mortality over the past few years. Here, we outline the protocol for a systematic review to investigate global temporal trends in all-cause mortality among patients with CKD at any stage from 1990 to current. We also aim to assess temporal trends in the mortality rate associated with the COVID-19 pandemic.
METHODS AND ANALYSIS: We will conduct a systematic review of studies reporting mortality for patients with CKD following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will search electronic databases, national and multiregional kidney registries and grey literature to identify observational studies that reported on mortality associated with any cause for patients with CKD of all ages with any stage of the disease. We will collect data between April and August 2023 to include all studies published from 1990 to August 2023. There will be no language restriction, and clinical trials will be excluded. Primary outcome will be temporal trends in CKD-related mortality. Secondary outcomes include assessing mortality differences before and during the COVID-19 pandemic, exploring causes of death and examining trends across CKD stages, country classifications, income levels and demographics.
ETHICS AND DISSEMINATION: A systematic review will analyse existing data from previously published studies and have no direct involvement with patient data. Thus, ethical approval is not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences.
PROSPERO REGISTRATION NUMBER: CRD42023416084.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
BMJ open - 14(2024), 4 vom: 03. Apr., Seite e078485 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tungsanga, Somkanya [VerfasserIn] |
---|
Links: |
---|
Themen: |
Chronic renal failure |
---|
Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/bmjopen-2023-078485 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370591305 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370591305 | ||
003 | DE-627 | ||
005 | 20240405234147.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240404s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/bmjopen-2023-078485 |2 doi | |
028 | 5 | 2 | |a pubmed24n1366.xml |
035 | |a (DE-627)NLM370591305 | ||
035 | |a (NLM)38569707 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tungsanga, Somkanya |e verfasserin |4 aut | |
245 | 1 | 0 | |a Global trends in chronic kidney disease-related mortality |b a systematic review protocol |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.04.2024 | ||
500 | |a Date Revised 05.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a INTRODUCTION: In recent decades, all-cause mortality has increased among individuals with chronic kidney disease (CKD), influenced by factors such as aetiology, standards of care and access to kidney replacement therapies (dialysis and transplantation). The recent COVID-19 pandemic also affected mortality over the past few years. Here, we outline the protocol for a systematic review to investigate global temporal trends in all-cause mortality among patients with CKD at any stage from 1990 to current. We also aim to assess temporal trends in the mortality rate associated with the COVID-19 pandemic | ||
520 | |a METHODS AND ANALYSIS: We will conduct a systematic review of studies reporting mortality for patients with CKD following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will search electronic databases, national and multiregional kidney registries and grey literature to identify observational studies that reported on mortality associated with any cause for patients with CKD of all ages with any stage of the disease. We will collect data between April and August 2023 to include all studies published from 1990 to August 2023. There will be no language restriction, and clinical trials will be excluded. Primary outcome will be temporal trends in CKD-related mortality. Secondary outcomes include assessing mortality differences before and during the COVID-19 pandemic, exploring causes of death and examining trends across CKD stages, country classifications, income levels and demographics | ||
520 | |a ETHICS AND DISSEMINATION: A systematic review will analyse existing data from previously published studies and have no direct involvement with patient data. Thus, ethical approval is not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences | ||
520 | |a PROSPERO REGISTRATION NUMBER: CRD42023416084 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Chronic renal failure | |
650 | 4 | |a Dialysis | |
650 | 4 | |a Mortality | |
650 | 4 | |a Renal transplantation | |
650 | 4 | |a Systematic Review | |
700 | 1 | |a Ghimire, Anukul |e verfasserin |4 aut | |
700 | 1 | |a Hariramani, Vinash K |e verfasserin |4 aut | |
700 | 1 | |a Abdulrahman, Abdullah |e verfasserin |4 aut | |
700 | 1 | |a Khan, Ana S |e verfasserin |4 aut | |
700 | 1 | |a Ye, Feng |e verfasserin |4 aut | |
700 | 1 | |a Kung, Janice Y |e verfasserin |4 aut | |
700 | 1 | |a Klarenbach, Scott |e verfasserin |4 aut | |
700 | 1 | |a Thompson, Stephanie |e verfasserin |4 aut | |
700 | 1 | |a Collister, David |e verfasserin |4 aut | |
700 | 1 | |a Srisawat, Nattachai |e verfasserin |4 aut | |
700 | 1 | |a Okpechi, Ikechi G |e verfasserin |4 aut | |
700 | 1 | |a Bello, Aminu K |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2011 |g 14(2024), 4 vom: 03. Apr., Seite e078485 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2024 |g number:4 |g day:03 |g month:04 |g pages:e078485 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2023-078485 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2024 |e 4 |b 03 |c 04 |h e078485 |